A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Phase 1/2 Recruiting 40 enrolled Cabaletta Bio

Non-randomizedSequentialOpen-labelTreatment

Summary

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

Timeline

Start: 2020-09-29
Primary completion: 2029-01
Completion: 2029-01

Publications

Shu J, Xie W, Chen Z, Offringa R, Hu Y, Mei H. The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases. Med. 2024 Jun 14;5(6):495-529. doi: 10.1016/j.medj.2024.03.016. Epub 2024 Apr 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DSG3-CAART	Cell therapy	—	Intravenous
Subject	resecabtagene autoleucel	Cell therapy	—	Intravenous

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Summary

Timeline

Publications

Drugs

Indications